Last reviewed · How we verify

Prophylaxis of deep vein thrombosis in patients undergoing abdominal surgery — Treatment Landscape & Competitive Intelligence

Prophylaxis of deep vein thrombosis in patients undergoing abdominal surgery (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prophylaxis of deep vein thrombosis in patients undergoing abdominal surgery, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Fragmin Dalteparin Sodium Pfizer Inc. Low molecular weight heparin (LMWH) Factor Xa and thrombin

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer Inc. · 1 drug in Prophylaxis of deep vein thrombosis in patients undergoing abdominal surgery

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prophylaxis of deep vein thrombosis in patients undergoing abdominal surgery:

Cite this brief

Drug Landscape (2026). Prophylaxis of deep vein thrombosis in patients undergoing abdominal surgery — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prophylaxis-of-deep-vein-thrombosis-in-patients-undergoing-abdominal-surgery. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing